Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

Stifel noted Johnson & Johnson started the fourth-quarter ... quarter and benefits from momentum gained by newly launched products throughout the year. Stifel analyst Rick Wise maintained a ...

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...

Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Innovation remains core, seen in new products such as SPRAVATO for depression and the OTTAVA robotic system. Johnson & Johnson recently concentrated on fostering innovations within its segments ...